43 related articles for article (PubMed ID: 38199780)
1. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P; Li L; Jiang X; Li Q
J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
[TBL] [Abstract][Full Text] [Related]
2. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
3. PD-L1
Allbee AW; Gerson J; Yang G; Bagg A
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38199780
[TBL] [Abstract][Full Text] [Related]
4. BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression.
Kang SY; Kim DG; Kim KM
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142641
[TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
6. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
[TBL] [Abstract][Full Text] [Related]
7. Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability.
Yang Y; Jain RK; Glenn ST; Xu B; Singh PK; Wei L; Hu Q; Long M; Hutson N; Wang J; Battaglia S; George S
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221012
[TBL] [Abstract][Full Text] [Related]
8. An unusual case of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing.
Han B; Kim S; Koh J; Bae JM; Yun H; Jeon YK
J Pathol Transl Med; 2022 Mar; 56(2):92-96. PubMed ID: 34775735
[TBL] [Abstract][Full Text] [Related]
9. Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Lee B; Lee H; Cho J; Yoon SE; Kim SJ; Park WY; Kim WS; Ko YH
Front Oncol; 2021; 11():628807. PubMed ID: 33777778
[TBL] [Abstract][Full Text] [Related]
10. Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma.
Chen C; Liu S; Jiang X; Huang L; Chen F; Wei X; Guo H; Shao Y; Li Y; Li W
Exp Hematol Oncol; 2021 Mar; 10(1):20. PubMed ID: 33722306
[TBL] [Abstract][Full Text] [Related]
11. Immune-Checkpoint Inhibitors in B-Cell Lymphoma.
Armengol M; Santos JC; Fernández-Serrano M; Profitós-Pelejà N; Ribeiro ML; Roué G
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430146
[TBL] [Abstract][Full Text] [Related]
12. Somatic Nonepigenetic Mismatch Repair Gene Aberrations Underly Most Mismatch Repair-Deficient Lynch-Like Tumors.
Elze L; Mensenkamp AR; Nagtegaal ID; van Zelst-Stams WAG; ; de Voer RM; Ligtenberg MJL
Gastroenterology; 2021 Mar; 160(4):1414-1416.e3. PubMed ID: 33253688
[No Abstract] [Full Text] [Related]
13. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma.
Tian T; Li J; Xue T; Yu B; Li X; Zhou X
Cancer Med; 2020 Apr; 9(7):2330-2342. PubMed ID: 32022486
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
